Diastolic Dysfunction in Rheumatoid Arthritis
Poor cardiovascular outcomes have been linked to inflammation and rheumatoid arthritis (RA). This includes higher rates of MI and heart failure (HF).
News
Gout: New Classification Criteria from ACR/EULAR
The American College of Rheumatology and the European League against Rheumatism joined forces to finalize classification criteria for gout, a condition that affects 8.3 million Americans.
A Controlled Trial of Yoga Benefits Arthritis Patients
Yoga and stretching appear to be important forms of exercise for patients with fibromyalgia, but their utility has seldom been explored in patients with rheumatoid or osteoarthritis.
Can Fibromyalgia in Children be Treated Without Medication?
The hallmarks of fibromyalgia -- widespread pain, poor sleep, effort intolerance, fatigue -- are difficult to manage and usually require medication and a multi-modal approach.
Is Early Use of TNFi in Spondyloarthritis Overkill or a Necessity?
Axial SpA (axSpA) is a chronic inflammatory disease that includes AS and non-radiographic axSpA (nr-axSpA).
Age and Comorbidity Contribute to Higher Death Risk Following Hip Fracture Surgery
Patients undergoing surgery for a hip fracture appear to have higher death rates than those having elective total hip replacement.
Funding for Rheumatology Research in Decline
The Rheumatology Research Foundation and Rheumatology News report that research projects funded by the National Institutes of Health (NIH) dropped by 52% from 2010 to 2014, while the number funded by private foundations fell by 29% over that period.
Monitoring of Novel Therapies in Rheumatology
The rheumatology therapeutic landscape has changed almost yearly in the last 15 years, with the introduction of at least 16 biologic or novel agents for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA), juvenile arthritis,
Adalimumab FDA Approved for Hidradenitis Suppurativa
Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
Dr. Olga Petryna
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
FDA Warns of Bone Fracture Risk and Lower BMD with Diabetes Drug
The FDA has strengthened its warnings for the type 2 diabetes drug canagliflozin (Invokana, Invokamet) and the apparent increased risk of bone fractures, and added new information about decreased bone mineral density.
Antibodies to 14-3-3η Found in Large Vessel Vasculitis
14-3-3η (eta) is a new test that may be useful in diagnosing patients with early rheumatoid arthritis. The test is 77% sensitive and 93% specific for RA and developers have found that antibodies against 14-3-3η may correlate with drug responsiveness.
